SCHEMBL1968068

SCHEMBL1968068

C[C@H](OCc1ccc(-c2ccccc2)cc1)C(=O)Cl

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PPARG P37231 2/20 0.47
PPARA Q07869 2/20 0.47
GAA P10253 2/20 0.46
CYP1A2 P05177 1/20 0.46
CYP2C9 P11712 1/20 0.46
PKM P14618 1/20 0.46
CYP2C19 P33261 1/20 0.46
IDO1 P14902 2/20 0.44
AGXT P21549 2/20 0.44
ABCC4 O15439 1/20 0.44
LMNA P02545 1/20 0.44
TSHR P16473 1/20 0.44
PTGS1 P23219 1/20 0.44
HTT P42858 1/20 0.44
ALDH1A1 P00352 2/20 0.43
FFAR1 O14842 1/20 0.43
MAPT P10636 1/20 0.43
HPGD P15428 1/20 0.43
NAAA Q02083 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12437213 1.00 PPARG (0.47) PPARGPPARAGAACYP1A2CYP2C9
SCHEMBL839677 0.90 ALDH1A1 (0.53) CYP1A2CYP2C9CYP2C19LMNATSHR
SCHEMBL5168366 0.90 ALDH1A1 (0.53) CYP1A2CYP2C9CYP2C19LMNATSHR
SCHEMBL5169494 0.90 ALDH1A1 (0.53) CYP1A2CYP2C9CYP2C19LMNATSHR
SCHEMBL28656889 0.88 ALDH1A1 (0.52) CYP1A2CYP2C9CYP2C19LMNATSHR
SCHEMBL3260466 0.87 GAA (0.57) PPARGPPARAGAACYP1A2CYP2C9
SCHEMBL1973572 0.87 GAA (0.57) PPARGPPARAGAACYP1A2CYP2C9
SCHEMBL7924569 0.85 KMT2A (0.49) GAACYP1A2CYP2C9PKMCYP2C19
SCHEMBL1968848 0.83 NAAA (0.48) GAACYP1A2CYP2C9PKMCYP2C19
SCHEMBL2221132 0.83 NAAA (0.48) GAACYP1A2CYP2C9PKMCYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9340493-B2 Hydroxamic acid derivatives useful as antibacterial agents PFIZER INC. (US) 2016-05-17 US disclosed
US-9340493-B2 Hydroxamic acid derivatives useful as antibacterial agents PFIZER INC. (US) 2016-05-17 US disclosed
US-20140206651-A1 Hydroxamic Acid Derivatives Useful As Antibacterial Agents PFIZER INC. (US) 2014-07-24 US disclosed
US-20140206651-A1 Hydroxamic Acid Derivatives Useful As Antibacterial Agents PFIZER INC. (US) 2014-07-24 US disclosed
US-8722686-B2 Hydroxamic acid derivatives useful as antibacterial agents PFIZER INC. (US) 2014-05-13 US disclosed
US-8722686-B2 Hydroxamic acid derivatives useful as antibacterial agents PFIZER INC. (US) 2014-05-13 US disclosed
US-20110178042-A1 Hydroxamic Acid Derivatives Useful as Antibacterial Agents PFIZER INC. (US) 2011-07-21 US disclosed
US-20110178042-A1 Hydroxamic Acid Derivatives Useful as Antibacterial Agents PFIZER INC. (US) 2011-07-21 US disclosed
EP-2334636-A2 HYDROXAMIC ACID DERIVATIVES USEFUL AS ANTIBACTERIAL AGENTS Pfizer Inc. (US) 2011-06-22 EP disclosed
WO-2010032147-A2 HYDROXAMIC ACID DERIVATIVES USEFUL AS ANTIBACTERIAL AGENTS PFIZER INC. (US) 2010-03-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140206651-A1 Hydroxamic Acid Derivatives Useful As Antibacterial Agents HCAR1, H1-0, HDAC1 PPARG 1140/4885PPARA 1655/4885GAA 156/4885
US-20110178042-A1 Hydroxamic Acid Derivatives Useful as Antibacterial Agents HCAR1, HDAC1, H1-0 PPARG 1181/4885PPARA 1586/4885GAA 162/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.